These studies evaluated the potential antiparkinsonian properties of the novel
dopamine D(3)/D(2) receptor agonist
S32504 [(+)-trans-3,4,4a,5,6, 10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth[1,2-b]-1,4-oxazine] in comparison with those of the clinically employed agonist
ropinirole. In rats with a unilateral,
6-hydroxydopamine lesion of the substantia nigra,
S32504 (0.0025-0.04 mg/kg, s.c.) more potently elicited contralateral rotation than S32601 [(-)-trans-3,4,4a,5,6, 10b-hexahydro-9-carbamoyl-4-propyl-2H-naphth-[1,2-b]-1,4-oxazine (its less active enantiomer)],
ropinirole, and
l-3,4-dihydroxyphenylalanine (
l-DOPA). Rotation elicited by
S32504 was blocked by the D(2)/D(3) receptor antagonists
haloperidol and
raclopride and by the D(2) antagonist L741,626 [4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)piperidin-4-ol], but not by the D(3) antagonist
S33084 [(3aR,9bS)-N-[4-(8-cyano-1,3a,4,9b-tetrahydro-3H-benzopyrano[3,4-c]
pyrrole-2-yl)-butyl]-(4-phenyl)
benzamide]. As assessed by dialysis in both lesioned and nonlesioned animals,
S32504 (0.04-2.5 mg/kg, s.c.) reduced striatal levels of
acetylcholine. This effect was blocked by
raclopride,
haloperidol, and L741,626 but not
S33084. In rats treated with
reserpine, hypolocomotion was reversed by
S32504 and, less potently, by
ropinirole. In "unprimed" marmosets treated with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, both s.c. (0.01-0.04 mg/kg) and p.o. (0.04-1.25 mg/kg) administration of
S32504 dose-dependently and rapidly (within 10 min) increased locomotor activity and reduced disability. Furthermore,
S32504 dose-dependently reversed
bradykinesia and improved posture in "
L-DOPA-primed" animals, whereas eliciting less pronounced
dyskinesia than
l-DOPA. Finally, in terminally differentiated SH-SY5Y cells presenting a dopaminergic phenotype,
S32504, but not S32601, abrogated the neurotoxic effects of
1-methyl-4-phenylpyridinium, an action inhibited by
raclopride and
S33084 but not L741,626.
Ropinirole was weakly neuroprotective in this model. In conclusion,
S32504 displays potent and stereospecific activity in rodent, primate, and cellular models of antiparkinsonian properties. Although activation of D(2) receptors is crucial to the motor actions of
S32504, engagement of D(3) receptors contributes to its neuroprotective properties.